Alzheimer's Disease - Healing Genes

Alzheimer’s Disease

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Allogeneic Human Mesenchymal Stem Cell Infusion Versus Placebo in Patients With Alzheimer’s Disease

A Phase, I Prospective, Randomized, Double-Blinded, Placebo-controlled, Trial to Evaluate the Safety and Potential Efficacy of Longeveron Allogeneic Human Mesenchymal Stem Cell (LMSCs) Infusion Versus Placebo in Patients With Alzheimer’s Disease

Phase 1


Researchers at hospitals in CA and FL seek patients with Alzheimer’s Disease to trial a treatment of donated (allogeneic) mesenchymal stem cells or placebo to test the treatments’ ability to reduce their symptoms over the next year.


  • Be 50 years to 80 years of age
  • Have a body mass of 45 – 150 kg
  • Not have any other neurodegenerative disease


  1. Prescreening at the study site to confirm eligibility of the patient to participate
  2. Infusion of the allogeneic stem cells
  3. Lab and psychological assessments will continue at Baseline, 2, 4, 13, 26, 39, and 52 weeks


The following locations are participating in the study:


United States, California

UCLA School of Medicine in Los Angeles, CA. Map.

Brain Matters Research in Delray Beach, FL. Map.

University of Miami Miller School of Medicine in Miami, FL. Map.

Miami Jewish Health in Miami, FL. Map.


Contact: Suzanne L Page  |  305-909-0850  |  [email protected]

Contact: Amy Drouillard  |  305-909-0840  |  [email protected]



Longeveron LLC

Or go online:

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader